Blood‐based biomarkers for Alzheimer's disease

A Leuzy, N Mattsson‐Carlgren, S Palmqvist… - EMBO molecular …, 2022 - embopress.org
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

[HTML][HTML] The role of short-chain fatty acids from gut microbiota in gut-brain communication

YP Silva, A Bernardi, RL Frozza - Frontiers in endocrinology, 2020 - frontiersin.org
A substantial body of evidence supports that the gut microbiota plays a pivotal role in the
regulation of metabolic, endocrine and immune functions. In recent years, there has been …

Association between sleep duration and cognitive decline

Y Ma, L Liang, F Zheng, L Shi, B Zhong… - JAMA network …, 2020 - jamanetwork.com
Importance An association between sleep duration and the trajectory of cognitive decline
has not been conclusively demonstrated. Objective To investigate the association between …

Peptide-based vaccines: current progress and future challenges

RJ Malonis, JR Lai, O Vergnolle - Chemical reviews, 2019 - ACS Publications
Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …

[HTML][HTML] Inflammation as a central mechanism in Alzheimer's disease

JW Kinney, SM Bemiller, AS Murtishaw… - Alzheimer's & Dementia …, 2018 - Elsevier
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized
by cognitive decline and the presence of two core pathologies, amyloid β plaques and …

Designing the next-generation clinical care pathway for Alzheimer's disease

H Hampel, R Au, S Mattke, WM van der Flier, P Aisen… - Nature Aging, 2022 - nature.com
The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

G Livingston, J Huntley, KY Liu, SG Costafreda… - The Lancet, 2024 - thelancet.com
Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

APP mouse models for Alzheimer's disease preclinical studies

H Sasaguri, P Nilsson, S Hashimoto, K Nagata… - The EMBO …, 2017 - embopress.org
Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

The economic burden of dementia in low-and middle-income countries (LMICs): a systematic review

SM Mattap, D Mohan, AM McGrattan, P Allotey… - BMJ global …, 2022 - gh.bmj.com
Introduction More than two-thirds of people with dementia live in low-and middle-income
countries (LMICs), resulting in a significant economic burden in these settings. In this …

[HTML][HTML] Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's …

A Cano, M Ettcheto, JH Chang, E Barroso… - Journal of Controlled …, 2019 - Elsevier
Abstract Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's
disease (AD) but its inherent instability limits bioavailability and effectiveness. We found that …